
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. is advancing its gene editing technologies, demonstrating significant durability with FVIII levels sustained at 80% over a 19-month period in its non-human primate model, indicating strong therapeutic potential for Hemophilia A treatment. The company's comprehensive suite of proprietary genome editing tools positions it uniquely in the genetic medicines sector, facilitating both in vivo gene editing for its pipeline and pursuit of technology out-licensing for ex vivo applications. With a robust pipeline targeting serious health conditions such as Refractory Hypertension and Wilson's disease, Metagenomi is well-positioned for future growth driven by its innovative therapeutics.
Bears say
Metagenomi Inc. reported a significant net loss of $19.9 million for the second quarter of 2025, equating to a loss of $0.54 per share, which raises concerns about the company's financial stability. Despite trading below its cash value, indicating potential upside, the company faces substantial risks including delays in clinical advancement and the possibility of unfavorable clinical data, particularly for key pipeline candidates like MGX-001 targeting Hemophilia A. Additionally, the potential for long-term dilution poses further challenges to shareholder value and may hinder investor confidence in the company’s future performance.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares